EGFR is commonly overexpressed in head and neck squamous cell carcinomas (HNSCCs) and EGFR inhibition is consequently an important treatment strategy for this cancer. In a recent paper, Agulnik ...

In patients with renal impairment, rocuronium and sugammadex are the primary choice for reversing neuromuscular blockade, ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso ... progression or death (95% CI 0.32-0.93, P=0.023). There was a near-15% absolute difference in ...

Objective Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of ...

EGFR-TKI 已成为 EGFR 突变晚期非小细胞肺癌（NSCLC）患者的标准治疗方案[1]，然而，约 2%~5% 的初治 EGFR 突变晚期 NSCLC 患者合并原发 MET 扩增，且接受 EGFR-TKI ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors.

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

SC amivantamab, in combination with LAZCLUZE, is recommended for adult patients with advanced NSCLC with epidermal growth factor receptor (EGFR) mutations. The recommended dosing is weekly from Weeks ...